Skip Navigation LinksHome > June 2014 - Volume 34 - Issue 2 > The Pathophysiology of Thyroid Eye Disease
Journal of Neuro-Ophthalmology:
doi: 10.1097/WNO.0000000000000132
State-of-the-Art Review

The Pathophysiology of Thyroid Eye Disease

Shan, Shannon J. C. MD, MSc; Douglas, Raymond S. MD, PhD

Section Editor(s): Biousse, Valérie MD; Galetta, Steven MD

Free Access
Article Outline
Collapse Box

Author Information

Wilmer Eye Institute (SJCS), The Johns Hopkins University School of Medicine, Baltimore, Maryland; and Kellogg Eye Center (RSD), University of Michigan, Ann Arbor, Michigan.

Address correspondence to Raymond S. Douglas, MD, PhD, Kellogg Eye Center, University of Michigan, 1000 Wall Street, Ann Arbor, MI 48105; E-mail: raydougl@med.umich.edu

The authors report no conflicts of interest.

Collapse Box

Abstract

The pathophysiology of thyroid eye disease (TED) is complex and incompletely understood. Orbital fibroblasts (OFs) seem to be the key effector cells that are responsible for the characteristic soft tissue enlargement seen in TED. They express potentially pathogenic autoantigens, such as thyrotropin receptor and insulin-like growth factor-1 receptor. An intricate interplay between these autoantigens and the autoantibodies found in Graves disease may lead to the activation of OFs, which then leads to increased hyaluronan production, proinflammatory cytokine synthesis, and enhanced differentiation into either myofibroblasts or adipocytes. Some of the OFs in TED patients seem to be derived from infiltrating fibrocytes. These cells originate from the bone marrow and exhibit both fibroblast and myeloid phenotype. In the TED orbit, they may mediate the orbital expansion and inflammatory infiltration. Last, lymphocytes and cytokines are intimately involved in the initiation, amplification, and maintenance of the autoimmune process in TED.

Thyroid eye disease (TED) is a vision-threatening condition that is most commonly associated with Graves disease (GD). Although the mechanism underlying the thyroid gland dysfunction in GD is now relatively well-characterized, the pathophysiology of TED is only beginning to be elucidated (Fig. 1). The common finding in TED that accounts for most of its clinical manifestations seems to be enlargement of orbital soft tissues (1). Radiographic evidence suggests an increase in the volume of both muscle and orbital fat (2). Histopathologic studies of the TED orbit reveal an extensive deposition of hyaluronan (a hydrophilic glycosaminoglycan) between muscle fibers, a widespread inflammatory infiltrate, and an overabundance of cytokines (3,4). These changes lead to interstitial edema and soft tissue expansion. Confined within the rigid orbital walls, such tissue enlargement can lead to increased intraorbital pressure, mechanical compression of orbital tissue including the optic nerve, and further inflammation (1).

FIG. 1
FIG. 1
Image Tools
Back to Top | Article Outline

ROLE OF ORBITAL FIBROBLASTS

The principal cell type responsible for the enlargement of orbital soft tissues in TED seems to be the orbital fibroblast (OF) (5–10). These cells are located in the interstitial space between muscle fibers, and within orbital fat and connective tissues (11). There are 2 subpopulations of OFs, which are classified based on whether or not they express the surface marker Thy1/CD90 (8,9,12,13). Thy1-expressing (Thy1+) OFs reside in the perimysium of the extraocular muscles. When activated, they can differentiate into myofibroblasts, the contractile element found in wound healing (12). Th1-deficient (Thy1) OFs are preadipocytes found throughout the orbit and can differentiate into mature adipocytes (8,12,14–17). The relative proportion of activated Thy1+ and Thy1 OFs may determine whether fibrosis or adipogenesis predominates in TED (8,12). In vitro studies have demonstrated that OFs from patients with TED (TED-OFs), more than those from healthy controls, are prone to activation, leading to proliferation, hyaluronan secretion, and soft tissue expansion (18–28). As will be discussed below, some OFs have robust expression of thyrotropin receptor (TSHR) and insulin-like growth factor-1 receptor (IGF-1R), 2 autoantigens that are thought to contribute to the activation of OFs in TED. Finally, TED-OFs are both more capable of secreting and responding to inflammatory cytokines compared with controls, possibly leading to amplification of the disease process (8,21,29–34).

Back to Top | Article Outline

ROLE OF FIBROCYTES

Fibrocytes are bone marrow–derived, fibroblast-like progenitor cells that circulate in the peripheral blood and may play a role in the pathogenesis of TED. They express the hematopoietic stem cell marker CD34 and the leukocyte common antigen CD45, and also various fibroblast proteins such as alpha-smooth muscle actin, collagen I and III, fibronectin, and vimentin (35). Fibrocytes are capable of migrating to sites of injury and differentiating into fibroblasts or adipocytes, participating in tissue remodeling and induction of T-cell proliferation (36,37). With both tissue-remodeling properties of fibroblasts, and proinflammatory properties of macrophages, fibrocytes have been implicated in various inflammatory or autoimmune-related fibrotic processes (38).

Fibrocytes are significantly more abundant in the peripheral circulation of patients with GD compared with healthy controls (39). Moreover, they have been shown to infiltrate both the orbital and thyroid tissues in GD patients (39,40). Within the orbit, fibrocytes exhibits remarkable plasticity and, similar to OFs, can differentiate into adipocytes or myofibroblasts (41). Furthermore, fibrocytes can be activated to produce cytokines in a similar manner as OFs. Patients with TED have markedly increased prevalence of CD40+ fibrocytes (42), which, in response to CD40 ligand, can produce interleukin (IL)-6, IL-8, macrophage chemoattractant protein 1, chemokine ligand 5 (CCL5), and tumor necrosis factor alpha (TNF-α), a profile very similar to that of activated OFs (42). Fibrocytes also resemble OFs in that they express both TSHR and IGF-1R on their surface. The potential functional relevance of this finding is discussed below. In aggregate, the above evidence introduces fibrocytes as a potential player in the pathogenesis of TED. Studies to further delineate the precise role of fibrocytes in TED are ongoing.

Back to Top | Article Outline

ROLE OF AUTOANTIGENS

OFs become abnormally activated in TED in both an antigen-dependent and antigen-independent manner. Several potential autoantigens have been identified in TED, although very few show any correlation with the presence or severity of TED (43–49). Nonetheless, 2 proteins that show significant promise as pathogenic autoantigens in TED are TSHR and IGF1-R.

Back to Top | Article Outline
Role of Thyrotropin Receptor

Thyrotropin receptor and its autoantibodies have a well-established role in the pathogenesis of GD (50). Accumulating evidence indirectly implicates them in the pathogenesis of TED. Autoantibodies against TSHR can be detected in up to 98% of patients with TED (51). Titers of the 2 subtypes of TSHR antibodies, thyroid stimulating immunoglobulins (TSI), which directly activate TSHR, and TSHR binding inhibitory immunoglobulins (TBII), which prevent TSH from binding TSHR, are both positively correlated with the clinical activity and severity of TED (47,48,51–53). It is unclear how these autoantibodies with seemingly opposite mechanisms of action on TSHR would positively correlate with each other and with the severity of disease. One hypothesis is that they may serve as a nonspecific marker of the B-cell–mediated autoimmune response.

The expression of TSHR, once thought to be limited to thyrocytes, has now been reported in a variety of cell types throughout the body, albeit at very low levels (54). Orbital tissues and primary cultures of OFs from patients with TED have increased TSHR expression compared with those from healthy controls (55–58). Moreover, TSHR expression in TED orbital tissues is higher in active disease compared with inactive disease (59). Although fibrocytes from both TED patients and healthy controls express TSHR, the fraction of TSHR-expressing fibrocytes is also significantly increased in the peripheral circulation of patients with TED (42). These TSHR-expressing fibrocytes from TED patients have an extremely high expression of TSHR per cell, rivaling thyrocytes (39,40,42). The mechanism underlying TSHR overexpression in OFs and fibrocytes remains unclear, but the above correlational evidence suggests the possibility that TSHR and its autoantibodies are involved in the pathogenesis of TED.

In vitro studies with cultured OFs yield further evidence that TSHR is a pathogenic autoantigen in TED. Treating Thy1-OFs (preadipocytes) with TSH or a stimulatory TSHR antibody, M22, leads to enhanced adipocyte differentiation as evidenced by increased expression of late-adipocyte genes adiponectin and leptin (60). On differentiation into mature adipocytes, these cells further increase the expression of TSHR, more so in TED-OFs than controls, which may contribute to the maintenance of disease (8,14–16,55,60–62). This TSHR-antibody–mediated activation of TED-OFs can be attenuated by a small molecule antagonist of the TSHR (63). Conversely, OFs transfected with a constitutively active TSHR mutant construct show stimulated hyaluronan production and early differentiation into adipocytes (64,65). The upregulation of TSHR in fibrocytes also seems to have a functional significance, as treatment of these cells with TSH leads to the production of the proinflammatory cytokines, TNF-α and IL-6 (39,40,42). The collective in vitro evidence above suggests that TSHR is a key pathogenic autoantigen in TED.

Several in vivo models of GD have been developed in recent decades, using various means to immunize mice with TSHR and induce TSHR antibody production (66–70). Although these models were able to produce hyperthyroidism, the orbital soft tissue changes as seen in TED were either not assessed or not present (66–70). An animal model with orbital features analogous to TED was recently reported. This model was generated by immunizing female BALB/c mice by in vivo muscle electroporation with the extracellular ligand-binding domain of TSHR (71,72). All immunized mice produced measurable TSHR antibodies, although most produced TBIIs rather than TSIs, and the mice developed hypothyroidism rather than hyperthyroidism (71). Nevertheless, immunized mice developed orbital changes that clinically, radiographically, and pathologically resembled those observed in humans with TED (71). This study provides the strongest in vivo evidence to-date supporting an integral role of TSHR in the pathogenesis of TED.

Back to Top | Article Outline
Role of IGF-1R

Another potentially pathogenic autoantigen in TED is the IGF-1R. This receptor tyrosine kinase and its signaling pathway have a wide spectrum of functions in tissue growth and development, and may participate in the pathogenesis of several metabolic, neoplastic, and immunologic diseases (73–77). The expression of IGF-1R is increased in TED-OFs compared with that in controls (78). The fraction of IGF-1R-expressing fibrocytes also seems to be increased in TED (39). When TED-OFs, but not control OFs, are treated with IGF1, they become activated and upregulate hyaluronan synthesis, similar to the response observed in these cells when treated with TSHR antibodies (25,79). This raises that possibility that IGF1 and TSHR antibodies may act through the same pathway. In addition, after the addition of IGF-1 or autoantibodies isolated from serum of GD patients (GD-IgG), TED-OFs, but not the control OFs, produce 2 powerful T-cell chemoattractants, IL-16 and CCL5 (80,81). On the contrary, recombinant human TSH could not induce this particular response in TED-OFs (80). This suggests that the GD-IgGs may be capable of activating the TED-OFs through a pathway independent of the TSHR, namely, the IGF-1R pathway (80).

There is increasing in vitro evidence now supporting the role of the IGF-1R pathway in the pathophysiology of TED. GD-IgGs can displace IGF1 from its high-affinity binding site on the cell surface of OFs (82). Although this binding site has not been confirmed to be a part of the IGF-1R, its dissociation constant is similar to that previously reported for IGF-1R (82–85). This suggests that GD-IgGs have an IGF-1R binding component. When IGF-1R function is disrupted in TED-OFs, either through the treatment with an IGF-1R blocking antibody or transfection with a dominant negative mutant IGF-1R, the GD-IgG–induced activation of TED-OFs is attenuated (81). Therefore, it seems that the GD-IgGs exert their effects on the TED-OFs at least in part through the IGF-1R pathway. The exact component of GD-IgGs that may be interacting with the IGF-1R is unknown. Autoantibodies against IGF-1R have been identified but have similar prevalence in TED patients and healthy controls, and the antibody concentration does not correlate with TED severity (86). Two mouse models of GD reported that some mice developed low titers of IGF-1R antibodies after immunization with TSHR (71,87). Interestingly, mice immunized with IGF-1R do not develop any obvious pathology, suggesting the importance of the thyroid autoantigens (71). Finally, it is possible that TSHR autoantibodies are the entities in GD-IgGs that are cross-reacting with IGF-1R.

IGF-1R and TSHR may work in a concerted fashion in the pathogenesis of TED. The IGF-1 and TSH have long been known to exert synergistic regulatory influences on target T-cell function, growth, and proliferation (74,88–90). This may in part be explained by the close physical relationship between the 2 receptors (78,91). Immunofluorescence staining shows that IGF-1R and TSHR colocalize to the perinuclear, cytoplasmic, and plasma membrane compartments in thyrocytes and OFs (78). Antibodies against either IGF-1R or TSHR can immunoprecipitate both proteins (78). Furthermore, an IGF-1R–blocking antibody can also block the signaling initiated by TSH, TSHR stimulating antibody, and GD-IgGs in TED-OFs (78,92). Whether or not these findings are due to antibody cross-reactivity between the 2 receptors is unclear. Studies to further characterize the physical and functional relationship between IGF-1R and TSHR and its implications in TED are ongoing.

Back to Top | Article Outline

ROLE OF LYMPHOCYTES

It is not known what initiates the immune response against autoantigens in autoimmune diseases. Factors such as susceptible genetic polymorphisms and environmental triggers such as infection have been proposed to contribute to this process in TED, but none have been definitively proven (93). Both T cells and B cells are intimately involved in the autoimmune response. Antigen-presenting cells present a pathogenic epitope of an autoantigen to CD4+ helper T cells, leading to T-cell activation and proliferation. The activated T cells may then either induce and sustain B cells to produce antibodies against the autoantigen, or be involved directly as autoreactive T cells in inflammation and/or cellular destruction (94). The tissue damage in autoimmune diseases arise from either direct attack by autoantibodies or autoreactive T cells, immune complex formation, or from local inflammation (94). Autoantibodies may also bind to receptors on target cells, causing enhanced activation or suppression of their signaling pathways (e.g., TSHR antibodies), leading to cellular dysfunction (94).

All of the aforementioned autoimmune processes likely partake in the pathophysiology of TED. Current evidence sheds light on a few more specific ways in which the T cells and TED-OF interact. Activated TED-OFs can produce potent T-cell chemoattractants, IL-16 and CCL5, facilitating the recruitment of T cells to the orbit (80,81). Once there, the T cells can reciprocate and activate TED-OFs either through cell–cell interaction or through diffusible cytokines. For example, the CD4+ T cells express CD145 (also known as CD40 ligand) on their cell surface. This ligand binds to CD40, a T-cell costimulatory protein expressed on the surface of TED-OFs in a higher amount as compared with controls (33). When treated with the cytokine interferon γ (IFN γ), TED-OFs increase their expression of CD40 even further (33,95). The binding of CD145 to CD40 triggers the activation of both the T cells and the TED-OFs. Activation of the T cells allows for the development of their effector functions including induction of B-cell differentiation and activation of monocytes and macrophages (96). The CD40-CD154–induced activation of TED-OFs lead to cell proliferation (97), increased synthesis of hyaluronan and prostaglandins (21), and production of proinflammatory cytokines including IL-6, IL-8, and macrophage chemoattractant protein-1 (33,95). These T-cell–mediated events contribute to the soft tissue remodeling and local inflammatory response in TED.

The principal functions of B cells include antibody production, antigen presentation, and cytokine production. B-cell-deficient mice fail to generate T-cell–mediated responses after immunization with TSHR (98). Therefore, B cells are indispensible to the initiation of the autoimmune process in GD. Rituximab is a monoclonal antibody that binds to the B-cell surface antigen CD20. The treatment of B cells with rituximab leads to the attenuation of CD20-dependent B-cell maturation, and reduced B-cell–mediated antigen presentation and cytokine production (99). More nonrandomized trials and case series have suggested that rituximab can induce lasting clinical improvement in TED (100–106). This confirms the critical role of B cells in the pathogenesis of TED. Several randomized controlled clinical trials are underway to further assess the efficacy and safety of this novel therapy for TED.

The expression of IGF-1R on T cells and B cells may further contribute to the autoimmune response against OFs in TED. A significantly higher fraction of the T-cells and B cells in GD patients expresses IGF-1R as compared with controls (107,108). This is evident in T cells from the blood and orbit (107), and in B cells from the blood, orbit, and bone marrow in these patients (108). Studies on discordant monozygotic twins show that this increase in the fraction of IGF-1R+ T cells and B cells in GD is not due to genetic determinants (109). For the T cells, display of IGF-1R protects these cells from apoptosis and promotes survival (107). For the B cells, increased IGF-1R display facilitates clonal expansion and propagates antibody production (108). These IGF-1R–mediated effects may contribute to the maintenance of the autoimmune response in TED.

Back to Top | Article Outline

ROLE OF CYTOKINES

Cytokines are small secreted proteins that are responsible for modulating the immune system. They are produced by each of the cell types discussed in this review. The aberrantly abundant expression of cytokines plays a central role in the pathogenesis of TED (110–116). There are 2 groups of cytokines: Th1-type (also known as type-1) cytokines produce proinflammatory responses, whereas Th2-type (also known as type-2) cytokines are essentially anti-inflammatory but can influence the production of antibodies (117). Different cytokine profiles are found in orbital tissues from TED patient with different stages of disease (111,118). In the early active stage of TED, Th1 cytokines such as IL-2, IFN-γ, TNF-α predominate (119). These proinflammatory cytokines can recruit more immune cells and amplify the immune response within the orbit (59,118,120). In the later, more inactive, stage of TED, Th2 cytokines such as IL-4, IL-6, IL-10, IL-13 predominate, and collectively, they stimulate B-cell proliferation and maturation into plasma cells, increasing antibody production (111,118,119). Furthermore, Th2-dominanted inflammatory responses have been well-documented to lead to fibrosis in various tissues including the heart, liver, and lungs (121–128). Thus, the overexpression of Th2 cytokines may also contribute to the fibrotic changes seen in the later-stage of TED.

An integral event in the pathogenesis of TED is cytokine-mediated activation of the OFs. Interestingly, OFs in culture exhibit a phenotype distinct from fibroblasts derived from other tissues such as the skin or lung: they show more exaggerated inflammatory response to cytokines (8,10,97,129). The TED-OFs and normal OFs have similarly exuberant response to activation by proinflammatory cytokines. Their activation by IL-1α, TGF-β, and leukoregulin leads to drastically increased synthesis of hyaluronan (19,20,24,27) and prostaglandins (29,30). Other activating effects of the cytokines on normal and TED-OFs have also been demonstrated. TGF-β can stimulate the differentiation of the Thy1+ subgroup OFs into myofibroblasts (12). IL-6 can promote adipogenesis and increase the expression of TSHR on Thy1+ OFs (61). Nevertheless, normal and TED-OFs have been shown to respond differently to a few cytokines. The proliferative capacity of TED-OFs was enhanced significantly more than normals in response to cytokines IL-1, IL-4, IGF-1, TGF-β, and platelet-derived growth factor (28). Furthermore, IL-1 stimulated hyaluronan secretion much more in TED-OFs than in normal OFs (26). Thus, TED-OFs may be even more sensitized to activational cues from cytokines than the already highly responsive normal OFs.

Another unique phenotype of the OFs is that on activation, they are fully capable of cytokine expression. TED-OFs produce higher levels of the proinflammatory cytokine IL-1 and lower levels of the neutralizing interleukin-1-receptor antagonist compared with normal OFs (130). This imbalance may lead to poorly opposed IL-1 signaling and an exaggerated inflammatory response. Other proinflammatory cytokines produced by activated TED-OFs include IL-6, IL-8, and macrophage chemoattractant protein-1 (8,33). Moreover, TED-OFs, but not normal OFs, express high levels of T-cell chemoattractants IL-16 and CCL5 when activated by treatment with IL-1 (34) or GD-IgGs (80), recruiting more inflammatory cells to the local tissue. Last, when treated with leukoregulin, IL-1, or recombinant CD40 ligand, TED-OFs are induced to express extremely high levels of prostaglandin E2, which is a potent mediator of inflammation (21,29–32). Collectively, this evidence solidifies the role of the OFs as the key effector cells in TED with a pronounced ability to respond to activating signals and a propensity to produce more proinflammatory signals of their own, hence generating the vicious cycle where inflammation begets more inflammation.

Back to Top | Article Outline

CONCLUSIONS

TED is an enigmatic vision-threatening autoimmune condition. Although our understanding of its pathophysiology has grown significantly in recent years, much remains to be discovered. Current evidence supports a central role of the OFs in the pathogenesis of TED. They become aberrantly and robustly activated in TED. The mechanism underlying this activation likely involves the autoantigens TSHR and IGF-1R and the GD autoantibodies, as well as interaction with immune cells and proinflammatory cytokines. Fibrocytes are progenitor cells that infiltrate the orbit and differentiate into OFs in TED, contributing to the pathogenesis of TED. As the disease mechanisms of TED continue to become elucidated, therapies that alter the course of disease can be developed.

Back to Top | Article Outline

REFERENCES

1. Bahn RS. Graves' ophthalmopathy. N Engl J Med. 2010; 362:726–738.

2. Forbes G, Gorman CA, Brennan MD, Gehring DG, Ilstrup DM, Earnest F. Ophthalmopathy of Graves' disease: computerized volume measurements of the orbital fat and muscle. AJNR Am J Neuroradiol. 1986; 7:651–656.

3. Hufnagel TJ, Hickey WF, Cobbs WH, Jakobiec FA, Iwamoto T, Eagle RC. Immunohistochemical and ultrastructural studies on the exenterated orbital tissues of a patient with Graves' disease. Ophthalmology. 1984; 91:1411–1419.

4. Smith TJ, Bahn RS, Gorman CA. Connective tissue, glycosaminoglycans, and diseases of the thyroid. Endocr Rev. 1989; 10:366–391.

5. Heufelder AE, Smith TJ, Gorman CA, Bahn RS. Increased induction of HLA-DR by interferon-gamma in cultured fibroblasts derived from patients with Graves' ophthalmopathy and pretibial dermopathy. J Clin Endocrinol Metab. 1991; 73:307–313.

6. Smith RS, Smith TJ, Blieden TM, Phipps RP. Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. Am J Pathol. 1997; 151:317–322.

7. Bartalena L, Wiersinga WM, Pinchera A. Graves' ophthalmopathy: state of the art and perspectives. J Endocrinol Invest. 2004; 27:295–301.

8. Smith TJ, Koumas L, Gagnon A, Bell A, Sempowski GD, Phipps RP, Sorisky A. Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2002; 87:385–392.

9. Wiersinga WM. Autoimmunity in Graves' ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors? J Clin Endocrinol Metab. 2011; 96:2386–2394.

10. Smith TJ, Tsai CC, Shih MJ, Tsui S, Chen B, Han R, Naik V, King CS, Press C, Kamat S, Goldberg RA, Phipps RP, Douglas RS, Gianoukakis AG. Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy. Thyroid. 2008; 18:983–988.

11. Boschi A, Daumerie C, Spiritus M, Beguin C, Senou M, Yuksel D, Duplicy M, Costagliola S, Ludgate M, Mang MC. Quantification of cells expressing the thyrotropin receptor in extraocular muscles in thyroid associated orbitopathy. Br J Ophthalmol. 2005; 89:724–729.

12. Koumas L, Smith TJ, Feldon S, Blumberg N, Phipps RP. Thy-1 expression in human fibroblast subsets defines myofibroblastic or lipofibroblastic phenotypes. Am J Pathol. 2003; 163:1291–1300.

13. Koumas L, Smith TJ, Phipps RP. Fibroblast subsets in the human orbit: Thy-1+ and Thy-1- subpopulations exhibit distinct phenotypes. Eur J Immunol. 2002; 32:477–485.

14. Sorisky A, Pardasani D, Gagnon A, Smith TJ. Evidence of adipocyte differentiation in human orbital fibroblasts in primary culture. J Clin Endocrinol Metab. 1996; 81:3428–3431.

15. Valyasevi RW, Erickson DZ, Harteneck DA, Dutton CM, Heufelder AE, Jyonouchi SC, Bahn RS. Differentiation of human orbital preadipocyte fibroblasts induces expression of functional thyrotropin receptor. J Clin Endocrinol Metab. 1999; 84:2557–2562.

16. Valyasevi RW, Harteneck DA, Dutton CM, Bahn RS. Stimulation of adipogenesis, peroxisome proliferator-activated receptor-gamma (PPARgamma), and thyrotropin receptor by PPARgamma agonist in human orbital preadipocyte fibroblasts. J Clin Endocrinol Metab. 2002; 87:2352–2358.

17. Feldon SE, O'Loughlin CW, Ray DM, Landskroner-Eiger S, Seweryniak KE, Phipps RP. Activated human T lymphocytes express cyclooxygenase-2 and produce proadipogenic prostaglandins that drive human orbital fibroblast differentiation to adipocytes. Am J Pathol. 2006; 169:1183–1193.

18. Bahn RS. Clinical review 157: pathophysiology of Graves' ophthalmopathy: the cycle of disease. J Clin Endocrinol Metab. 2003; 88:1939–1946.

19. Korducki JM, Loftus SJ, Bahn RS. Stimulation of glycosaminoglycan production in cultured human retroocular fibroblasts. Invest Ophthalmol Vis Sci. 1992; 33:2037–2042.

20. Smith TJ, Wang HS, Evans CH. Leukoregulin is a potent inducer of hyaluronan synthesis in cultured human orbital fibroblasts. Am J Physiol. 1995; 268:C382–C388.

21. Cao HJ, Wang HS, Zhang Y, Lin HY, Phipps RP, Smith TJ. Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression. Insights into potential pathogenic mechanisms of thyroid-associated ophthalmopathy. J Biol Chem. 1998; 273:29615–29625.

22. Kaback LA, Smith TJ. Expression of hyaluronan synthase messenger ribonucleic acids and their induction by interleukin-1beta in human orbital fibroblasts: potential insight into the molecular pathogenesis of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 1999; 84:4079–4084.

23. Han R, Smith TJ. T helper type 1 and type 2 cytokines exert divergent influence on the induction of prostaglandin E2 and hyaluronan synthesis by interleukin-1beta in orbital fibroblasts: implications for the pathogenesis of thyroid-associated ophthalmopathy. Endocrinology. 2006; 147:13–19.

24. Spicer AP, Kaback LA, Smith TJ, Seldin MF. Molecular cloning and characterization of the human and mouse UDP-glucose dehydrogenase genes. J Biol Chem. 1998; 273:25117–25124.

25. Smith TJ, Hoa N. Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J Clin Endocrinol Metab. 2004; 89:5076–5080.

26. Krieger CC, Gershengorn MC. A modified ELISA accurately measures secretion of high molecular weight hyaluronan (HA) by Graves' disease orbital cells. Endocrinology. 2014; 155:627–634.

27. Tan GH, Dutton CM, Bahn RS. Interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptor inhibit IL-1-induced glycosaminoglycan production in cultured human orbital fibroblasts from patients with Graves' ophthalmopathy. J Clin Endocrinol Metab. 1996; 81:449–452.

28. Heufelder AE, Bahn RS. Modulation of Graves' orbital fibroblast proliferation by cytokines and glucocorticoid receptor agonists. Invest Ophthalmol Vis Sci. 1994; 35:120–127.

29. Han R, Tsui S, Smith TJ. Up-regulation of prostaglandin E2 synthesis by interleukin-1beta in human orbital fibroblasts involves coordinate induction of prostaglandin-endoperoxide H synthase-2 and glutathione-dependent prostaglandin E2 synthase expression. J Biol Chem. 2002; 277:16355–16364.

30. Wang HS, Cao HJ, Winn VD, Rezanka LJ, Frobert Y, Evans CH, Sciaky D, Young DA, Smith TJ. Leukoregulin induction of prostaglandin-endoperoxide H synthase-2 in human orbital fibroblasts. An in vitro model for connective tissue inflammation. J Biol Chem. 1996; 271:22718–22728.

31. Cao HJ, Smith TJ. Leukoregulin upregulation of prostaglandin endoperoxide H synthase-2 expression in human orbital fibroblasts. Am J Physiol. 1999; 277:C1075–C1085.

32. Young DA, Evans CH, Smith TJ. Leukoregulin induction of protein expression in human orbital fibroblasts: evidence for anatomical site-restricted cytokine-target cell interactions. Proc Natl Acad Sci U S A. 1998; 95:8904–8909.

33. Hwang CJ, Afifiyan N, Sand D, Naik V, Said J, Pollock SJ, Chen B, Phipps RP, Goldberg RA, Smith TJ, Douglas RS. Orbital fibroblasts from patients with thyroid-associated ophthalmopathy overexpress CD40: CD154 hyperinduces IL-6, IL-8, and MCP-1. Invest Ophthalmol Vis Sci. 2009; 50:2262–2268.

34. Sciaky D, Brazer W, Center DM, Cruikshank WW, Smith TJ. Cultured human fibroblasts express constitutive IL-16 mRNA: cytokine induction of active IL-16 protein synthesis through a caspase-3-dependent mechanism. J Immunol. 2000; 164:3806–3814.

35. Bucala R, Spiegel LA, Chesney J, Hogan M, Cerami A. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med. 1994; 1:71–81.

36. Chesney J, Bacher M, Bender A, Bucala R. The peripheral blood fibrocyte is a potent antigen-presenting cell capable of priming naive T cells in situ. Proc Natl Acad Sci U S A. 1997; 94:6307–6312.

37. Quan TE, Cowper S, Wu SP, Bockenstedt LK, Bucala R. Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol. 2004; 36:598–606.

38. Peng H, Herzog EL. Fibrocytes: emerging effector cells in chronic inflammation. Curr Opin Pharmacol. 2012; 12:491–496.

39. Douglas RS, Afifiyan NF, Hwang CJ, Chong K, Haider U, Richards P, Gianoukakis AG, Smith TJ. Increased generation of fibrocytes in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2010; 95:430–438.

40. Smith TJ, Padovani-Claudio DA, Lu Y, Raychaudhuri N, Fernando R, Atkins S, Gillespie EF, Gianoukakis AG, Miller BS, Gauger PG, Doherty GM, Douglas RS. Fibroblasts expressing the thyrotropin receptor overarch thyroid and orbit in Graves' disease. J Clin Endocrinol Metab. 2011; 96:3827–3837.

41. Hong KM, Belperio JA, Keane MP, Burdick MD, Strieter RM. Differentiation of human circulating fibrocytes as mediated by transforming growth factor-beta and peroxisome proliferator-activated receptor gamma. J Biol Chem. 2007; 282:22910–22920.

42. Gillespie EF, Papageorgiou KI, Fernando R, Raychaudhuri N, Cockerham KP, Charara LK, Goncalves AC, Zhao SX, Ginter A, Lu Y, Smith TJ, Douglas RS. Increased expression of TSH receptor by fibrocytes in thyroid-associated ophthalmopathy leads to chemokine production. J Clin Endocrinol Metab. 2012; 97:E740–E746.

43. Hutfless S, Matos P, Talor MV, Caturegli P, Rose NR. Significance of prediagnostic thyroid antibodies in women with autoimmune thyroid disease. J Clin Endocrinol Metab. 2011; 96:E1466–E1471.

44. Ludgate M, Swillens S, Mercken L, Vassart G. Homology between thyroglobulin and acetylcholinesterase: an explanation for pathogenesis of Graves' ophthalmopathy? Lancet. 1986; 2:219–220.

45. Mizokami T, Salvi M, Wall JR. Eye muscle antibodies in Graves' ophthalmopathy: pathogenic or secondary epiphenomenon? J Endocrinol Invest. 2004; 27:221–229.

46. Gunji K, Kubota S, Stolarski C, Wengrowicz S, Kennerdell JS, Wall JR. A 63 kDa skeletal muscle protein associated with eye muscle inflammation in Graves' disease is identified as the calcium binding protein calsequestrin. Autoimmunity. 1999; 29:1–9.

47. Gerding MN, van der Meer JW, Broenink M, Bakker O, Wiersinga WM, Prummel MF. Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clin Endocrinol (Oxf). 2000; 52:267–271.

48. Eckstein AK, Plicht M, Lax H, Hirche H, Quadbeck B, Mann K, Steuhl KP, Esser J, Morganthaler NG. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies. Clin Endocrinol (Oxf). 2004; 61:612–618.

49. Khoo TK, Bahn RS. Pathogenesis of Graves' ophthalmopathy: the role of autoantibodies. Thyroid. 2007; 17:1013–1018.

50. Weetman AP. Graves' disease. N Engl J Med. 2000; 343:1236–1248.

51. Ponto KA, Kanitz M, Olivo PD, Pitz S, Pfeiffer N, Kahaly GJ. Clinical relevance of thyroid-stimulating immunoglobulins in Graves' ophthalmopathy. Ophthalmology. 2011; 118:2279–2285.

52. Eckstein AK, Plicht M, Lax H, Neuhauser M, Mann K, Lederbogen S, Heckmann C, Esser J, Morgenthaler NG. Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab. 2006; 91:3464–3470.

53. Lytton SD, Ponto KA, Kanitz M, Matheis N, Kohn LD, Kahaly GJ. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy. J Clin Endocrinol Metab. 2010; 95:2123–2131.

54. Davies T, Marians R, Latif R. The TSH receptor reveals itself. J Clin Invest. 2002; 110:161–164.

55. Starkey KJ, Janezic A, Jones G, Jordan N, Baker G, Ludgate M. Adipose thyrotrophin receptor expression is elevated in Graves' and thyroid eye diseases ex vivo and indicates adipogenesis in progress in vivo. J Mol Endocrinol. 2003; 30:369–380.

56. Bahn RS, Dutton CM, Natt N, Joba W, Spitzweg C, Heufelder AE. Thyrotropin receptor expression in Graves' orbital adipose/connective tissues: potential autoantigen in Graves' ophthalmopathy. J Clin Endocrinol Metab. 1998; 83:998–1002.

57. Crisp MS, Lane C, Halliwell M, Wynford-Thomas D, Ludgate M. Thyrotropin receptor transcripts in human adipose tissue. J Clin Endocrinol Metab. 1997; 82:2003–2005.

58. Stadlmayr W, Spitzweg C, Bichlmair AM, Heufelder AE. TSH receptor transcripts and TSH receptor-like immunoreactivity in orbital and pretibial fibroblasts of patients with Graves' ophthalmopathy and pretibial myxedema. Thyroid. 1997; 7:3–12.

59. Wakelkamp IM, Bakker O, Baldeschi L, Wiersinga WM, Prummel MF. TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves' ophthalmopathy patients. Clin Endocrinol (Oxf). 2003; 58:280–287.

60. Kumar S, Nadeem S, Stan MN, Coenen M, Bahn RS. A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves' ophthalmopathy. J Mol Endocrinol. 2011; 46:155–163.

61. Jyonouchi SC, Valyasevi RW, Harteneck DA, Dutton CM, Bahn RS. Interleukin-6 stimulates thyrotropin receptor expression in human orbital preadipocyte fibroblasts from patients with Graves' ophthalmopathy. Thyroid. 2001; 11:929–934.

62. Kumar S, Coenen MJ, Scherer PE, Bahn RS. Evidence for enhanced adipogenesis in the orbits of patients with Graves' ophthalmopathy. J Clin Endocrinol Metab. 2004; 89:930–935.

63. Turcu AF, Kumar S, Neumann S, Coenen M, Iyer S, Chiriboga P, Gershengoin MC, Bahn RS. A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy. J Clin Endocrinol Metab. 2013; 98:2153–2159.

64. Zhang L, Baker G, Janus D, Paddon CA, Fuhrer D, Ludgate M. Biological effects of thyrotropin receptor activation on human orbital preadipocytes. Invest Ophthalmol Vis Sci. 2006; 47:5197–5203.

65. Zhang L, Bowen T, Grennan-Jones F, Paddon C, Giles P, Webber J, Steadman R, Ludgate M. Thyrotropin receptor activation increases hyaluronan production in preadipocyte fibroblasts: contributory role in hyaluronan accumulation in thyroid dysfunction. J Biol Chem. 2009; 284:26447–26455.

66. McLachlan SM, Nagayama Y, Rapoport B. Insight into Graves' hyperthyroidism from animal models. Endocr Rev. 2005; 26:800–832.

67. Ludgate M. Animal models of Graves' disease. Eur J Endocrinol. 2000; 142:1–8.

68. Dagdelen S, Kong YC, Banga JP. Toward better models of hyperthyroid Graves' disease. Endocrinol Metab Clin North Am. 2009; 38:343–354.

viii


69. Wiesweg B, Johnson KT, Eckstein AK, Berchner-Pfannschmidt U. Current insights into animal models of Graves' disease and orbitopathy. Horm Metab Res. 2013; 45:549–555.

70. Baker G, Mazziotti G, von Ruhland C, Ludgate M. Reevaluating thyrotropin receptor-induced mouse models of Graves' disease and ophthalmopathy. Endocrinology. 2005; 146:835–844.

71. Moshkelgosha S, So PW, Deasy N, Diaz-Cano S, Banga JP. Cutting edge: retrobulbar inflammation, adipogenesis, and acute orbital congestion in a preclinical female mouse model of Graves' orbitopathy induced by thyrotropin receptor plasmid-in vivo electroporation. Endocrinology. 2013; 154:3008–3015.

72. Rickards C, Buckland P, Smith BR, Hall R. The interaction of Graves' IgG with the thyrotrophin receptor. FEBS Lett. 1981; 127:17–21.

73. Smith TJ, Hegedus L, Douglas RS. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy. Best Pract Res Clin Endocrinol Metab. 2012; 26:291–302.

74. Smith TJ. Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacol Rev. 2010; 62:199–236.

75. Bateman JM, McNeill H. Insulin/IGF signalling in neurogenesis. Cell Mol Life Sci. 2006; 63:1701–1705.

76. Kurmasheva RT, Houghton PJ. IGF-I mediated survival pathways in normal and malignant cells. Biochim Biophys Acta. 2006; 1766:1–22.

77. Walenkamp MJ, Wit JM. Genetic disorders in the growth hormone - insulin-like growth factor-I axis. Horm Res. 2006; 66:221–230.

78. Tsui S, Naik V, Hoa N, Hwang CJ, Afifiyan NF, Sinha Hikim A, Gianoukakis AG, Douglas RS, Smith TJ. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease. J Immunol. 2008; 181:4397–4405.

79. Imai Y, Odajima R, Inoue Y, Shishiba Y. Effect of growth factors on hyaluronan and proteoglycan synthesis by retroocular tissue fibroblasts of Graves' ophthalmopathy in culture. Acta Endocrinol (Copenh). 1992; 126:541–552.

80. Pritchard J, Horst N, Cruikshank W, Smith TJ. Igs from patients with Graves' disease induce the expression of T cell chemoattractants in their fibroblasts. J Immunol. 2002; 168:942–950.

81. Pritchard J, Han R, Horst N, Cruikshank WW, Smith TJ. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol. 2003; 170:6348–6354.

82. Weightman DR, Perros P, Sherif IH, Kendall-Taylor P. Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy. Autoimmunity. 1993; 16:251–257.

83. Jonas HA, Harrison LC. The human placenta contains two distinct binding and immunoreactive species of insulin-like growth factor-I receptors. J Biol Chem. 1985; 260:2288–2294.

84. Rosenfeld RG, Dollar LA. Characterization of the somatomedin-C/insulin-like growth factor I (SM-C/IGF-I) receptor on cultured human fibroblast monolayers: regulation of receptor concentrations by SM-C/IGF-I and insulin. J Clin Endocrinol Metab. 1982; 55:434–440.

85. Tollefsen SE, Thompson K, Petersen DJ. Separation of the high affinity insulin-like growth factor I receptor from low affinity binding sites by affinity chromatography. J Biol Chem. 1987; 262:16461–16469.

86. Minich WB, Dehina N, Welsink T, Schwiebert C, Morgenthaler NG, Kohrle J, Eckstein A, Schomburg L. Autoantibodies to the IGF1 receptor in Graves' orbitopathy. J Clin Endocrinol Metab. 2013; 98:752–760.

87. Zhao SX, Tsui S, Cheung A, Douglas RS, Smith TJ, Banga JP. Orbital fibrosis in a mouse model of Graves' disease induced by genetic immunization of thyrotropin receptor cDNA. J Endocrinol. 2011; 210:369–377.

88. Kimura T, Van Keymeulen A, Golstein J, Fusco A, Dumont JE, Roger PP. Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr Rev. 2001; 22:631–656.

89. Tramontano D, Cushing GW, Moses AC, Ingbar SH. Insulin-like growth factor-I stimulates the growth of rat thyroid cells in culture and synergizes the stimulation of DNA synthesis induced by TSH and Graves'-IgG. Endocrinology. 1986; 119:940–942.

90. Rapoport B, McLachlan SM. The thyrotropin receptor in Graves' disease. Thyroid. 2007; 17:911–922.

91. Kohn LD, Alvarez F, Marcocci C, Kohn AD, Corda D, Hoffman WE, Tombaccini D, Valente WA, de Luca M, Santisteban P, Grollman EF. Monoclonal antibody studies defining the origin and properties of autoantibodies in Graves' disease. Ann N Y Acad Sci. 1986; 475:157–173.

92. Kumar S, Iyer S, Bauer H, Coenen M, Bahn RS. A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in Graves' orbital fibroblasts: inhibition by an IGF-I receptor blocking antibody. J Clin Endocrinol Metab. 2012; 97:1681–1687.

93. McLachlan SM, Rapoport B. Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity. Endocr Rev. 2014; 35:59–105.

94. Janeway CA Jr, Travers P, Walport M, Shlomchik MJ. Immunobiology: The Immune System in Health and Disease. , 5th edition. New York, NY: Garland Science, 2001 .

95. Sempowski GD, Rozenblit J, Smith TJ, Phipps RP. Human orbital fibroblasts are activated through CD40 to induce proinflammatory cytokine production. Am J Physiol. 1998; 274:C707–C714.

96. Grewal IS, Flavell RA. The role of CD40 ligand in costimulation and T-cell activation. Immunol Rev. 1996; 153:85–106.

97. Feldon SE, Park DJ, O'Loughlin CW, Nguyen VT, Landskroner-Eiger S, Chang D, Thatcher TH, Phipps RP. Autologous T-lymphocytes stimulate proliferation of orbital fibroblasts derived from patients with Graves' ophthalmopathy. Invest Ophthalmol Vis Sci. 2005; 46:3913–3921.

98. Ueki I, Abiru N, Kobayashi M, Nakahara M, Ichikawa T, Eguchi K, Nagayama Y. B cell-targeted therapy with anti-CD20 monoclonal antibody in a mouse model of Graves' hyperthyroidism. Clin Exp Immunol. 2011; 163:309–317.

99. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol. 2003; 14:520–535.

100. Vannucchi G, Campi I, Bonomi M, Covelli D, Dazzi D, Curro N, Simonetta S, Bonara P, Personi L, Guastella C, Wall J, Beck-Peccozi P, Salvi M. Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions. Clin Exp Immunol. 2010; 161:436–443.

101. Bonara P, Vannucchi G, Campi I, Rossi S, Cantoni F, Frugoni C, Sbrozzi F, Guastella Cm Avignone S, Beck-Peccoz P, Salvi M. Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for Graves' ophthalmopathy. Clin Rev Allergy Immunol. 2008; 34:118–123.

102. Salvi M, Vannucchi G, Campi I, Curro N, Dazzi D, Simonetta S, Bonara P, Rossi I, Sina C. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol. 2007; 156:33–40.

103. Salvi M, Vannucchi G, Campi I, Beck-Peccoz P. Rituximab in the treatment of thyroid eye disease: science fiction? Orbit. 2009; 28:251–255.

104. Silkiss RZ, Reier A, Coleman M, Lauer SA. Rituximab for thyroid eye disease. Ophthal Plast Reconstr Surg. 2010; 26:310–314.

105. Salvi M, Vannucchi G, Curro N, Introna M, Rossi S, Bonara P, Covelli D, Dazzi D, Guastella C, Pignataro L, Ratiglia R, Golay J, Beck-Peccoz P. Small dose of rituximab for Graves orbitopathy: new insights into the mechanism of action. Arch Ophthalmol. 2012; 130:122–124.

106. Minakaran N, Ezra DG. Rituximab for thyroid-associated ophthalmopathy. Cochrane Database Syst Rev. 2013; 5:CD009226

107. Douglas RS, Gianoukakis AG, Kamat S, Smith TJ. Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves' disease may carry functional consequences for disease pathogenesis. J Immunol. 2007; 178:3281–3287.

108. Douglas RS, Naik V, Hwang CJ, Afifiyan NF, Gianoukakis AG, Sand D, Kamat S, Smith TJ. B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. J Immunol. 2008; 181:5768–5674–5774–.

109. Douglas RS, Brix TH, Hwang CJ, Hegedus L, Smith TJ. Divergent frequencies of IGF-I receptor-expressing blood lymphocytes in monozygotic twin pairs discordant for Graves' disease: evidence for a phenotypic signature ascribable to nongenetic factors. J Clin Endocrinol Metab. 2009; 94:1797–1802.

110. Gianoukakis AG, Khadavi N, Smith TJ. Cytokines, Graves' disease, and thyroid-associated ophthalmopathy. Thyroid. 2008; 18:953–958.

111. Hiromatsu Y, Yang D, Bednarczuk T, Miyake I, Nonaka K, Inoue Y. Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2000; 85:1194–1199.

112. Pappa A, Calder V, Ajjan R, Fells P, Ludgate M, Weetman AP, Lightman S. Analysis of extraocular muscle-infiltrating T cells in thyroid-associated ophthalmopathy (TAO). Clin Exp Immunol. 1997; 109:362–369.

113. Heufelder AE, Bahn RS. Detection and localization of cytokine immunoreactivity in retro-ocular connective tissue in Graves' ophthalmopathy. Eur J Clin Invest. 1993; 23:10–17.

114. Natt N, Bahn RS. Cytokines in the evolution of Graves' ophthalmopathy. Autoimmunity. 1997; 26:129–136.

115. Kumar S, Bahn RS. Relative overexpression of macrophage-derived cytokines in orbital adipose tissue from patients with Graves' ophthalmopathy. J Clin Endocrinol Metab. 2003; 88:4246–4250.

116. van Steensel L, Paridaens D, van Meurs M, van Hagen PM, van den Bosch WA, Kuijpers RW, Drexhage HA, Hooijkaas H, Dik WA. Orbit-infiltrating mast cells, monocytes, and macrophages produce PDGF isoforms that orchestrate orbital fibroblast activation in Graves' ophthalmopathy. J Clin Endocrinol Metab. 2012; 97:E400–E408.

117. Berger A. Th1 and Th2 responses: what are they? BMJ. 2000; 321:424

118. Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev. 2003; 24:802–835.

119. Aniszewski JP, Valyasevi RW, Bahn RS. Relationship between disease duration and predominant orbital T cell subset in Graves' ophthalmopathy. J Clin Endocrinol Metab. 2000; 85:776–780.

120. de Carli M, D'Elios MM, Mariotti S, Marcocci C, Pinchera A, Ricci M, Romagnani S, del Prete G. Cytolytic T cells with Th1-like cytokine profile predominate in retroorbital lymphocytic infiltrates of Graves' ophthalmopathy. J Clin Endocrinol Metab. 1993; 77:1120–1124.

121. Chiaramonte MG, Donaldson DD, Cheever AW, Wynn TA. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J Clin Invest. 1999; 104:777–785.

122. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol. 1997; 24:328–332.

123. Kanellakis P, Ditiatkovski M, Kostolias G, Bobik A. A pro-fibrotic role for interleukin-4 in cardiac pressure overload. Cardiovasc Res. 2012; 95:77–85.

124. Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V, Shipley JM, Gotwais P, Noble P, Chen Q, Senior RM, Elias JA. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med. 2001; 194:809–821.

125. O'Reilly S. Role of interleukin-13 in fibrosis, particularly systemic sclerosis. Biofactors. 2013; 39:593–596.

126. Shimamura T, Fujisawa T, Husain SR, Kioi M, Nakajima A, Puri RK. Novel role of IL-13 in fibrosis induced by nonalcoholic steatohepatitis and its amelioration by IL-13R-directed cytotoxin in a rat model. J Immunol. 2008; 181:4656–4665.

127. Wu D, Ahrens R, Osterfeld H, Noah TK, Groschwitz K, Foster PS, Steinbrecher KA, Rothenberg ME, Stroyer NF, Matthaei KI, Finkelman FD, Hogan SP. Interleukin-13 (IL-13)/IL-13 receptor alpha1 (IL-13Ralpha1) signaling regulates intestinal epithelial cystic fibrosis transmembrane conductance regulator channel-dependent Cl- secretion. J Biol Chem. 2011; 286:13357–13369.

128. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, Zhang Y, Elias JA. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest. 1999; 103:779–788.

129. van Steensel L, Paridaens D, Dingjan GM, van Daele PL, van Hagen PM, Kuijpers RW, van den Bosch WA, Drexhage HA, Hooijkaas H, Dik WA. Platelet-derived growth factor-BB: a stimulus for cytokine production by orbital fibroblasts in Graves' ophthalmopathy. Invest Ophthalmol Vis Sci. 2010; 51:1002–1007.

130. Cao HJ, Han R, Smith TJ. Robust induction of PGHS-2 by IL-1 in orbital fibroblasts results from low levels of IL-1 receptor antagonist expression. Am J Physiol Cell Physiol. 2003; 284:C1429–C1437.

Copyright © 2014 by North American Neuro-Ophthalmology Society

Login